Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RJDG RJD Green Inc.’s Silex Holdings Division Acquires the Assets of JSI Interiors
https://finance.yahoo.com/news/rjd-green-inc-silex-holdings-130000684.html
$INTV Partnership For GLP-1
https://finance.yahoo.com/news/integrated-ventures-inc-announces-strategic-124500730.html
$SSII Revolutionizing Surgery:
https://finance.yahoo.com/news/revolutionizing-surgery-ss-innovations-international-123000647.html
$RITE See Shareholder Memo with updates on the status of various ongoing projects. Management remains focused on the acquisitions in RITE’s pipeline.
https://mineral-rite.com/wp-content/uploads/2024/09/2024-09-23-Letter-to-RITE-Shareholders-UPDATE-10_vFNL.pdf
$RITE See Shareholder Memo with updates on the status of various ongoing projects. Management remains focused on the acquisitions in RITE’s pipeline.
https://mineral-rite.com/wp-content/uploads/2024/09/2024-09-23-Letter-to-RITE-Shareholders-UPDATE-10_vFNL.pdf
$XXII 22nd Century Updates Strategic Growth Initiatives for VLN Low Nicotine Tobacco Products.
https://finance.yahoo.com/news/22nd-century-updates-strategic-growth-115500015.html
$VVPR "Proposed all stock merger values VivoPower equity at US$556 million (implying a share price of US$101 per VVPR share) with FAST equity valued at US$578 million"
$XONI Xtreme Fighting Championships Announces Innovative NIL Partnership with World-Class College Wrestlers and Combat-Sport Veterans
https://finance.yahoo.com/news/xtreme-fighting-championships-announces-innovative-160400010.html
$ARBTF $ARQ Argo Oil Update
https://finance.yahoo.com/news/argo-oil-122900263.html
Bright Mountain Media (OTCQB: $BMTM) Adds to the team with AdTech Veteran Tom Triscari as Director and Compensation Committee Chair
https://finance.yahoo.com/news/bright-mountain-media-otcqb-bmtm-130000142.html
$CBDW Adnexus Biotechnologies Partners with 1606 Corp.
https://www.accesswire.com/918717/adnexus-biotechnologies-partners-with-1606-corp-for-strategic-investment-to-revolutionize-ai-driven-drug-discovery
$DDDX Several years ago, 3D Printing stocks started out with a bang but then fizzled. Now AI ChatGPT tells us that 3D printing stocks are back
https://richardacavalli.wixsite.com/greenplanetmicrocaps/3d-printing-to-explode
$DDD $NMDN $ONVO $VLD $MKFG
$SSII SS Innovations Conducts Interactive Meeting with the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration FDA
https://finance.yahoo.com/news/ss-innovations-conducts-interactive-meeting-123000503.html
$RJDG Mark Gould has been appointed as the Tulsa Division Manager for Silex Holdings Inc., a division of RJD Green Inc.
https://finance.yahoo.com/news/rjd-green-inc-silex-holdings-140700515.html
$IDVV News: IEC Announces Update on Winners Waygers AI Powered Sports Handicapping Assistant
Las Vegas, Nevada--(Newsfile Corp. - September 10, 2024) - International Endeavors Corp. (OTC PINK: IDVV) ("IEC"), a technology holdings company announced that its artificial intelligence (AI) powered sports handicapping assistant has received additional pro subscribers, and its free beta version has topped 4000 subscribers.
Previously the company announced the launch of http://winnersaygers.com, a one of a kind artificial intelligence (AI) powered sports handicapping program in beta mode. Today we are pleased to announce that the free beta service has already received 4000 subscribers.
Current subscribers are being given picks that the AI is generating for the current NFL season, and plans are to convert subscribers to several paid options towards the end of October as the AI learns more data during the current season and becomes more efficient in its strategy. Last season the AI had over a 60% win rate, with an increasingly better win rate as the season progresses and the AI is able to use more up to date information. The current focus is building subscribers while perfecting the AI's thought process.
We have received additional subscribers for the professional AI handicapping version. Used by professional handicappers that helped to develop the tools and datasets for the AI. The pro tools do not make picks for professionals, but instead help them to acquire data at a much faster pace and allow them to increase their action. We anticipate reaching up to 100 subscribers by year end. Due to that nature of the handicapping community, Pro subscribers are acquired by referrals. Each paying a negotiable signup fee of up to $10,000 per license along with a monthly subscription of $1000 to $2000.
Winners Waygers spokesperson Marrion Lewis stated "We are on track with offering the service to the mainstream. Converting the pro version to a more user friendly mainstream style has been an undertaking, but one that our team is doing well. We're confident that a product will be there that can revolutionize the industry."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/222813_21b8d136c42aeaa5_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222813
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/222813/130
$RFR.CN Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) today advises shareholders that results from our initial soil sampling campaign on our Parbec Gold Project
https://www.thenewswire.com/press-releases/1LPRFXN68-gold-mineralization-extended-into-sediments-at-parbec-with-soil-survey-results.html
$RFHRF Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) Featured
https://www.miningnewswire.com/renforth-resources-inc-cse-rfr-otcqb-rfhrf-releases-status-report-in-sector-noted-as-essential-contributor/
$SSII Appointment of Dr. Fredric Moll:
https://www.globenewswire.com/en/news-release/2024/09/10/2943651/0/en/SS-Innovations-Welcomes-Father-of-Surgical-Robotics-Dr-Fredric-Moll-to-Board.html
$BMTM Bright Mountain Media Appoints Industry Veteran Joe Pergola as Director and Audit Committee Chair
https://finance.yahoo.com/news/bright-mountain-media-appoints-industry-130000276.html
$BLQC BlockQuarry Corp. Expands Operational Focus on AI
https://finance.yahoo.com/news/blockquarry-corp-expands-operational-focus-120000336.html
$RITE met with several quality contacts at the National Investment Bankers Association meeting last week. Talks are progressing with purpose with multiple members as RITE’s story continues to unfold. #MineralRite #RITE #PreciousMetalMining #InvestorRelations #OTCMarkets
$RITE met with several quality contacts at the National Investment Bankers Association meeting last week. Talks are progressing with purpose with multiple members as RITE’s story continues to unfold. #MineralRite #RITE #PreciousMetalMining #InvestorRelations #OTCMarkets
— Mineralrite Corporation (@Mineralrite) September 9, 2024
$ARQ $ARBTF Argo Gold Inc's. #CSE: July 2024 #oil production
https://www.newsfilecorp.com/release/222641/Argos-July-2024-Oil-Production
$ARBTF $ARQ Argo's June 2024 Oil Production
https://finance.yahoo.com/news/argos-june-2024-oil-production-132200591.html
$RFHRF Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) Releases Update on Parbec Gold Deposit
https://www.networknewswire.com/renforth-resources-inc-cse-rfr-otcqb-rfhrf-releases-update-on-parbec-gold-deposit/
$NWPN Good Looking #AI Lotto Play.
Dear The Now Corporation (OTC:NWPN) Shareholders,
— @thenowcorp (@thenowcorp) July 22, 2024
Ken Williams has resigned as an officer and director. The company has acquired an artificial intelligence company with the appointment of a phenomenal CEO and Director to lead us into the future. She will be releasing a press…
$BTTC Bitech Technologies Signs Term Sheet of $80 Million Investment Tax Credit for Its Flagship BESS Project
https://finance.yahoo.com/news/bitech-technologies-signs-term-sheet-113000785.html
$IDVV: Winners Waygers AI Powered Sports Handicapping Assistant Launched In Beta
Carlsbad, California--(Newsfile Corp. - August 15, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced that its WITech.ai division launched a one of a kind artificial intelligence (AI) powered sports handicapping assistant today.
We are pleased to announce the launch of winnerswaygers.com in a free beta mode today thus expanding our AI's ability into sports handicapping. IEC's WITech division plans to expand the service quickly into a subscription based model featuring all major sports using the popularity of the NFL football and fantasy betting season as a catalyst to make users aware of the service.
The AI is currently used by professional handicappers that helped to develop the tools and datasets for the AI. WITech is transforming the current complex model into a user friendly service that will appeal to all.
Current plans are to launch in phases starting with a beta mode offering users the ability to sign up for the service for free. Upon the start of the NFL season in September 2024 users will begin receiving handicapping information from the AI to assist in their decision making.
Our goal after beta is to launch our paid subscription service featuring an interactive sports handicapping bot in Mid October 2024 along with an expansion into Hockey and Basketball. We will be offering a discount to any users of the beta version who wish to upgrade at that time.
We are planning in Q4 of 2024 to begin charging $77 per league selected, for example NFL, and will offer an all sports league package for $247 per year/season. As previously indicated there will be a discount for beta members. At that time the beta version will become a free weekly newsletter featuring one pick to allow potential paid subscribers to see how the service works. We have been seeing massive interest in this service and feel we will have thousands of subscribers as the paid service gets rolled out.
Winners Waygers spokesperson Marrion Lewis stated, "We are excited offer the service to the mainstream. For far too long only professionals have had access to the complex data used to make more accurate sports bets. We plan to change the game. The NFL is the most popular sport to bet, so it is fitting to use it for our launch. I'm personally rooting for the chiefs, but we'll let the AI decide."
IDVV board member Ray Valdez stated, "This is the first expansion of the company into adult related, and more importantly recession resilient sectors. With the potential of many thousands of subscribers we are looking forward to discussing winners waygers along with other opportunities the company is pursuing shortly."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com.
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone:833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/220044_9ae4a1780431c9ef_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220044
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/220044/130
$BTTC Bitech Technologies Corporation (OTCQB: BTTC) Featured with technological innovation
https://thestreetreports.com/bitech-technologies-otcqb-bttc-revolutionizes-grid-stability-with-advanced-energy-storage-and-smart-energy-solutions/
$BMTM Bright Mountain Media Appoints Elaine Riddell as Non-Executive Director Bringing 15 Years of Experience
https://www.globenewswire.com/news-release/2024/09/04/2940546/0/en/Bright-Mountain-Media-Appoints-Elaine-Riddell-as-Non-Executive-Director-Bringing-15-Years-of-Experience-Driving-Transformative-Growth.html
$CBDW 1606 Corp. Signs Letter of Intent to Acquire a Strategic Stake in Adnexus, a Leading AI Biotech Company
https://finance.yahoo.com/news/1606-corp-signs-letter-intent-120000809.html
$SSII SS Innovations International, Inc. Announces First Mantra Surgical Robotic System Sale in South America
https://finance.yahoo.com/news/ss-innovations-international-inc-announces-131500902.html
$GNPX News: Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes
AUSTIN, Texas, Sept. 3, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in September 2024.
Event: H.C. Wainwright 26th Annual Global Investment Conference
Conference Dates: September 9-13, 2024
Presentation Date: On-demand September 9-11, 2024 in the conference portal (virtual)
Presenter: Ryan Confer, Genprex's President, Chief Executive Officer and Chief Financial Officer
Mr. Confer will virtually deliver an overview of the Company's pioneering gene therapies for cancer and diabetes and will be available for virtual meetings with investors through the conference platform.
Event: Chardan's 8th Annual Genetic Medicines Conference
Dates: September 30 – October 1, 2024
Location: Westin Grand Central in New York, NY
Company Participant: Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing
Mr. Gallagher will be available for in-person meetings with conference attendees.
For those interested in meeting Genprex management during these conferences, please request a meeting through the conference portal or reach out to Investor Relations at investors@genprex.com.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
https://c212.net/c/img/favicon.png?sn=DA96104&sd=2024-09-03 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-to-present-and-participate-at-upcoming-september-investor-and-industry-conferences-302236356.html
$DTII Defense Technologies International Corp. announces the conclusion of assessments of the Passive Portal system by NUSTL for their SAVER program.
https://finance.yahoo.com/news/defense-technologies-international-corp-conclusion-130000556.html
$XONI Xtreme One Entertainment Board Approves Strategic Growth Plan & Announces $10 Million Capital Raise
https://www.globenewswire.com/en/news-release/2024/09/03/2939706/0/en/Xtreme-One-Entertainment-Board-Approves-Strategic-Growth-Plan-Announces-10-Million-Capital-Raise-to-Accelerate-Investment-in-XFC-and-other-Xtreme-One-Brands.html
$SSII SS Innovations Issues Update on Status of Audit
https://finance.yahoo.com/news/ss-innovations-issues-status-audit-125500303.html
$RFHRF MiningNewsBreaks – Why Renforth Resources Inc. $RFR.CN $RFHRF $9RR.F Is ‘One to Watch’
https://www.miningnewswire.com/miningnewsbreaks/miningnewsbreaks-why-renforth-resources-inc-cse-rfr-otcqb-rfhrf-fse-9rr-is-one-to-watch/
$SPEV Shorepower Technologies Wins Phase 1 Contract with US Department of Energy
https://finance.yahoo.com/news/shorepower-technologies-wins-phase-1-090000691.html
$GNPX: Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes
Video Highlights Recent Oncology Clinical Development Program Updates
AUSTIN, Texas, Aug. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the Company's oncology clinical development program.
The Acclaim-1 clinical trial is evaluating the combination of the Company's lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and Genentech's Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Dr. Berger remarked on the two positive patient outcomes in Acclaim-1:
"Both of these patients' outcomes are fairly remarkable in terms of their prolonged Progression Free Survival (PFS) among patients in the study who were progressing on their previous treatment when they came into the study. It's very compelling, particularly, that one of those patients has maintained this benefit for more than two years. And over time, the patients' side effects with the combination of REQORSA and Tagrisso have diminished rather than increased over time."
Dr. Berger's commentary on the positive patient outcome in Acclaim-3:
"In the Acclaim-3 study, the first patient treated in the Phase 1 dose escalation portion of the trial has had a positive response since enrollment and starting maintenance therapy. The patient has a partial remission (PR) from the start of maintenance therapy until after the second course, which is when the first CT scan is done. This is the first dose group in this study, and there is a second higher dose group to come. The patient's response is remarkable, and it is very unusual to have a PR during maintenance therapy. We believe these results bode very well for the study."
On recent updates to the Company's oncology clinical development program, Dr. Berger stated:
"To build on these positive patient results, we are making changes to our clinical development program both in the Acclaim-1 and Acclaim-2 studies. In the Acclaim-1 study, we are removing one of the cohorts in Phase 2a, which will allow us to advance more quickly. The Acclaim-2 study is being closed to further enrollment. It has been slow to enroll patients, mainly because there are hundreds of other very similar studies that evaluate new treatments after patients have progressed on Keytruda®. We certainly intend to continue to treat patients in this study until they have disease progression. We also believe closing to further enrollment is the right thing to do so that we can focus our limited resources on the fastest way to being able to enroll patients and get clinical data.
We're very excited by these positive patient responses, and we look forward to advancing REQORSA through the clinic. We believe that streamlining our efforts to do so is the best way to use our resources and to move our program forward."
To watch the video, please visit Genprex's website at https://www.genprex.com/videos/.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the initial patient responses to REQORSA treatments and the potential and promise of these responses, which are demonstrating early evidence of efficacy with a favorable safety profile; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
https://c212.net/c/img/favicon.png?sn=DA84592&sd=2024-08-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-releases-new-video-featuring-chief-medical-officer-discussing-positive-patient-outcomes-in-two-lung-cancer-clinical-trials-302223226.html
SOURCE Genprex, Inc.
$INTV Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products
https://finance.yahoo.com/news/integrated-ventures-announces-strategic-entry-124300666.html
$VVPR Looks Great - Here is Why
$VVPR looks great on the chart. Higher highs and higher lows. Moreover, the stock is now trading above all the key Moving averages.
Next stop could be $3.50+++
$LRGR Fortun Reports a 245% Surge in Business
https://www.globenewswire.com/en/news-release/2024/08/27/2936256/0/en/Fortun-Reports-a-245-Surge-in-Business-Advances-Since-June-2024.html
Wanna kick some woke liberalism butt?
Get some shares of $CBMJ.....Just started https://Patriot.TV - Conservative Broadcasting Network
And they got Gen Mike Flynnn on the Board of Directors.
I'm gonna call her the Little Sister of $DJT.
Z
$BHAT - Unlike traditional gold companies, Blue Hat is not merely a gold trader earning from the buy-sell spread; rather, it will generate revenue from various aspects of the gold supply chain. Additionally, Blue Hat's gold sources are not limited to newly mined gold but also include gold that recycle from market consumers.
https://www.globenewswire.com/en/news-release/2024/08/15/2930903/0/en/Blue-Hat-Expands-into-Gold-Trading-with-Strategic-Partnerships-As-Gold-Prices-Rise-Amid-Economic-Optimism.html
$LVVV LiveWire Ergogenics Reports Financial Results for Q2 2024
https://www.otcmarkets.com/otcapi/company/dns/news/document/76806/content
$HALB Introducing Tri-axTM TBI Nasal Spray
https://www.globenewswire.com/en/news-release/2024/08/26/2935424/0/en/Halberd-Corp-Issues-Letter-to-Shareholders.html
$KAYS A New Portland Shroom Service Center Offers Halloween Trips and Bargain-Priced Psychedelic Stock
https://www.wweek.com/news/2024/08/21/a-new-portland-shroom-service-center-offers-halloween-trips-and-bargain-priced-psychedelic-stock/
$ALLO Current Institutional Ownership Percentage 83.63% up from 63%
187 Institutional Holders 165,517,865 Total Shares Held
https://www.marketbeat.com/stocks/NASDAQ/ALLO/institutional-ownership/
ALLO Price target from $8.00 to $14.00 depending on who is giving it. Now 2.59
georgie18
Thursday, August 22, 2024 9:56:12 AM
Post#
654721
of 654851
ALLO...Looking for Break/Hold of $3.70 range resistance ...the $5.80 range resistance...
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |